Mo Qatanani, Scholar Rock Holding Corp's Chief Scientific Officer, disposed of 8,484 shares of the company's common stock on February 23, 2026, realizing approximately $399,350 in proceeds.
The share sales were carried out in three separate trades. Executed prices ranged from $46.52 to $48.66 per share. In detail, 7,427 shares were sold at a weighted average price of $46.9422, 857 shares at a weighted average price of $47.8588, and 200 shares at a weighted average price of $48.48.
These transactions took place while Scholar Rock's stock traded close to its 52-week high of $49.82, following a 41% gain over the prior six months.
After completing these sales, Qatanani is recorded as directly holding 98,445 restricted stock units (RSUs) in Scholar Rock.
Market context and analyst coverage
Third-party platform analysis cited in company reporting identifies Scholar Rock as appearing overvalued at its current price and places the stock on a "Most Overvalued" list. That same analysis notes that seven analysts have revised their earnings estimates downward for the coming period. The platform also points to additional insights available to subscribers, including a comprehensive Pro Research Report covering Scholar Rock and more than 1,400 U.S. equities.
Several equity research actions and coverage moves have accompanied recent company developments. H.C. Wainwright increased its price target for Scholar Rock to $58 from $44 while maintaining a Buy rating, citing favorable commentary from key opinion leaders in neurology about the company's drug candidate apitegromab. UBS initiated coverage with a Buy rating and set a $60 price target, highlighting the potential of Scholar Rock's development pipeline, and Cantor Fitzgerald reiterated an Overweight rating and expressed confidence in the approval prospects for apitegromab in spinal muscular atrophy.
Regulatory and manufacturing update
Scholar Rock disclosed that its manufacturing partner, Catalent Indiana, received a warning letter from the U.S. Food and Drug Administration. Despite the warning letter to the contract manufacturer, Scholar Rock remains optimistic about resubmitting its biologics license application for apitegromab and plans for a U.S. launch in 2026, contingent on regulatory approval. The company is working with the FDA to address the issues cited in the letter.
Combined, the insider sale, the platform valuation signals, analyst coverage changes, and the manufacturing partner's regulatory interaction provide investors with a set of concrete updates on Scholar Rock's financial positioning and development pathway for its lead candidate.
Summary of the transaction
- Insider: Mo Qatanani, Chief Scientific Officer
- Date of sale: February 23, 2026
- Total shares sold: 8,484
- Proceeds: Approximately $399,350
- Price range: $46.52 - $48.66
- Remaining direct holdings: 98,445 RSUs